Toronto, Ontario–(Newsfile Corp. – October 10, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia”, or the “Company”), is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders held on Wednesday, October 9, 2024. A total of 9.9% of the issued and outstanding common shares of the Company were represented either in person or by proxy at the meeting.
On a vote by ballot, the following 3 nominees proposed by the Company were elected as Directors of Braxia Scientific to serve until the Company’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:
| Director | For | % | Withheld | % |
| Roger McIntyre | 20,509,914 | 73.16% | 7,524,405 | 26.84% |
| Ahmed Shehata | 20,575,171 | 73.39% | 7,459,148 | 26.61% |
| Jerry Habuda | 20,214,841 | 72.11% | 7,819,478 | 27.89% |
In addition to the election of all nominees listed as directors in the management information circular, dated August 27, 2024 (the “Circular”), Braxia shareholders approved all other resolutions placed before the meeting. These included appointing DMCL as auditors for the Company for the ensuing year and the special resolution approving a sale of all or substantially all of the Company’s assets in connection with the Company’s proposed transaction (the “Transaction”) with Kris Kratiuk (the “Purchaser”), and in particular sale of the assets of the Canadian Rapid Treatment Center of Excellence Inc., the Company’s wholly-owned subsidiary and clinic operator, all as more particularly described in the Circular. The Company intends to proceed to close the Transaction with the Purchaser as soon as possible.
For more details on the matters covered at the annual meeting, please refer to the Company’s management information circular available on SEDAR+ at www.sedarplus.ca. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR+.
About Braxia Scientific Corp.
Braxia Scientific is a medical research and telemedicine company with a clinic that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on owning and operating multidisciplinary clinics, providing treatments in-person and virtually for mental health disorders. Through its wholly owned subsidiary, Braxia Health (formerly the Canadian Rapid Treatment Center of Excellence Inc.), operates a multidisciplinary community-based clinic offering rapid-acting treatments for depression located in Mississauga.
ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre”
Dr. Roger S. McIntyre
Chairman & CEO
– 30 –
FOR FURTHER INFORMATION PLEASE CONTACT:
Braxia Scientific Corp.
Tel: 416-762-2138
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.